Compare CTSO & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | MDAI |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 48.8M |
| IPO Year | 2008 | N/A |
| Metric | CTSO | MDAI |
|---|---|---|
| Price | $0.81 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.38 | $3.25 |
| AVG Volume (30 Days) | 69.2K | ★ 215.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,503,908.00 | N/A |
| Revenue This Year | $7.29 | N/A |
| Revenue Next Year | $8.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.60 | $1.04 |
| 52 Week High | $1.39 | $3.21 |
| Indicator | CTSO | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 71.21 | 35.32 |
| Support Level | $0.62 | $1.32 |
| Resistance Level | $0.85 | $1.76 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 84.73 | 12.00 |
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.